Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 5/20 | 0.36 |
| ▸ | HTR1A | P08908 | 4/20 | 0.36 |
| ▸ | HTR1B | P28222 | 4/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.35 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 3/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17310149 | 0.79 | CA1 (0.40) | CA1CA2HSD11B1HTR1DHTR1A | |
| SCHEMBL15720571 | 0.79 | LOXL2 (0.42) | CA1CA2HSD11B1HTR1DHTR1A | |
| SCHEMBL23674532 | 0.77 | CA1 (0.39) | CA1CA2HSD11B1HTR1DHTR1A | |
| SCHEMBL28741615 | 0.76 | RIPK2 (0.41) | CA1CA2HSD11B1HTR1DHTR1A | |
| SCHEMBL28741515 | 0.76 | HTR1D (0.40) | CA1CA2HSD11B1HTR1DHTR1A | |
| SCHEMBL6481315 | 0.75 | PDE4A (0.39) | CA1CA2HSD11B1ESR2HTR1D | |
| SCHEMBL30384914 | 0.74 | PDE4A (0.41) | CA1CA2HSD11B1HTR1DHTR1A | |
| SCHEMBL5308131 | 0.74 | CA2 (0.42) | CA1CA2HSD11B1HTR1DHTR1A | |
| SCHEMBL28978575 | 0.73 | CA1 (0.36) | CA1CA2HSD11B1HTR1DHTR1A | |
| SCHEMBL5748165 | 0.72 | CCR1 (0.44) | CA1CA2PDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608839-A1 | SPIROCYCLE CONTAINING BICYCLIC HETEROARYL COMPOUNDS | Protego Biopharma, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20240174695-A1 | Spirocycle Containing Bicyclic Heteroaryl Compounds | PROTEGO BIOPHARMA, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024092040-A1 | SPIROCYCLE CONTAINING BICYCLIC HETEROARYL COMPOUNDS | PROTEGO BIOPHARMA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-2137179-B1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2586778-A2 | Pyridazinone derivatives useful as glucan synthase inhibitors | Merck Sharp & Dohme Corp. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| WO-2008115381-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | MAN2A1, GYS2, MANBA | CA1 4563/4885CA2 3206/4885HSD11B1 1714/4885 |
| US-20240174695-A1 | Spirocycle Containing Bicyclic Heteroaryl Compounds | BCL6, BCL6B, BCL9 | CA1 4633/4885CA2 4545/4885HSD11B1 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.